FY17 DOD Joint Program Committee-2/Military Infectious Diseases Research Program (JPC-2/MIDRP)

Fiscal Year 2017 (FY17) funding opportunities for the Department of Defense (DOD) Joint Program Committee-2/Military Infectious Diseases Research Program (JPC-2/MIDRP) that are being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).

Applied Research Award

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Deadline: 5:00 p.m. Eastern time (ET), January 25, 2016

• Invitation to Submit an Application: March 7, 2016

• Application Submission Deadline: 11:59 p.m. ET, May 9, 2016

• End of Application Verification Period: 5:00 p.m. ET, May 12, 2016

• Peer Review: July 2016

• Programmatic Review: August 2016

FY17 JPC-2/MIDRP Applied Research Award Focus Areas

To meet the intent of the FY17 JPC-2/MIDRP Applied Research Award (ARA) mechanism, applications MUST specifically address at least one of the FY17 JPC-2/MIDRP ARA Focus Areas related to combat-related or trauma-induced wound infections listed below. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below will not be considered for funding.

FOCUS AREAS:

• Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multipathogen/multi-phenotype characterization of antimicrobial resistance patterns.

• Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical infection management decisions (e.g., optimal wound closure time, optimal duration of antibiotic administration for osteomyelitis).

• Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.

APPLICABLE TO ALL FOCUS AREAS:

• Studies involving carbapenem-resistant organisms are particularly sought.

• Preference will be given to approaches that address infections with one or more MDROs, particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extendedspectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens.

• Preference will be given to studies leading toward topical treatments for prevention and management of wound infection.

Clinical Study Award

SUBMISSION AND REVIEW DATES AND TIMES

• Pre-Application Deadline: 5:00 p.m. Eastern time (ET), January 25, 2016

• Invitation to Submit an Application: March 7, 2016

• Application Submission Deadline: 11:59 p.m. ET, May 9, 2016

• End of Application Verification Period: 5:00 p.m. ET, May 12, 2016

• Peer Review: July 2016

• Programmatic Review: August 2016

FY17 JPC-2/MIDRP Clinical Study Award Focus Areas

To meet the intent of the FY17 JPC-2/MIDRP Clinical Study Award (CSA) mechanism, applications MUST contain only one clinical trial/testing with a distinct study design and address at least one of the Focus Areas listed below. Applications focused on areas other than those listed below will not be considered for funding.

FOCUS AREAS:

Therapeutics. Evaluation of optimum preventive or directive therapies for combatrelated or trauma-induced wound infections using Food and Drug Administration (FDA)-approved drugs, biologics, or devices either alone or in combination. Studies focusing on new indications of FDA-approved drugs/biologics/devices or investigational new drugs/biologics/devices will be accepted.

Rapid detection of pathogens and/or anti-microbial drug resistance markers. Evaluation of a functional prototype device or assay for the rapid detection of pathogens and/or anti-microbial drug resistance markers in combat-related or traumainduced wounds. Research outcomes should support the development of an FDA regulated device or assay.

  • Rapid detection of biomarkers. Evaluation of a functional prototype device or assay for the rapid detection of novel and specific in vivo or in vitro biomarkers (from wound, serum, saliva, or urine) that predict development of infection or discriminate between infection and colonization. Research outcomes should support the development of an FDA-regulated device or assay.

APPLICABLE TO ALL FOCUS AREAS:

• Studies involving carbapenem-resistant organisms are particularly sought.

• Preference will be given to approaches that address infections with one or more multidrug-resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s